SymBio Pharmaceuticals Ltd

SymBio Pharmaceuticals maintains a strong liquidity position, with cash and equivalents amounting to ¥6.36 billion, representing 87.7% of total assets. The company's liquidity FPT (free cash flow to total debt) is not applicable due to the absence of long-term debt, and its current ratio of 9.12 indicates a robust short-term liquidity buffer. However, the company reported negative operating cash flow of ¥1.13 billion, suggesting operational inefficiencies or high R&D expenditures.

Profitability metrics reveal significant challenges for SymBio Pharmaceuticals. The company reported a net loss of ¥763.94 million and an operating loss of ¥908.34 million, resulting in a negative return on equity (ROE) of -11.85% and a return on assets (ROA) of -10.55%. These figures are well below the industry median for ROE and ROA, which typically range between 10-15% for profitable pharmaceutical firms. The gross margin of 76.4% is relatively strong, but the inability to convert this into operating profit highlights structural inefficiencies or high R&D costs.

Geographically, SymBio Pharmaceuticals' revenue is concentrated in Japan, with no disclosed international operations in the latest financials. The company operates in a single business segment focused on pharmaceutical development and commercialization, with no material diversification across therapeutic areas or product lines. This concentration increases exposure to domestic regulatory and reimbursement risks.

The company's growth trajectory is mixed. While revenue of ¥686.56 million is reported for the latest period, the operating loss of ¥908.34 million indicates a lack of profitability. The outlook for the current fiscal year suggests continued investment in R&D and product development, with no immediate signs of revenue acceleration. The absence of long-term debt and the high cash balance suggest the company is in a position to fund operations without external financing for the near term.

Risk factors for SymBio Pharmaceuticals include the high volatility of R&D pipelines and the potential for regulatory delays in drug approvals. The company's dilution risk is currently low, with no near-term pressure from share issuance or convertible debt. However, the negative net income and operating cash flow could necessitate future capital raises, which may dilute existing shareholders. The risk assessment indicates no immediate filing-based liquidity or dilution flags, but the company's financial performance remains a concern.

Recent events include the continued development of its pipeline, particularly in oncology and rare diseases. The company has not disclosed any major regulatory approvals or product launches in the latest filings. Analyst estimates for the last actual EPS and revenue were -95.12 JPY and ¥1.31 billion, respectively, indicating a significant gap between actual performance and expectations.

The company maintains a zero debt-to-equity ratio, ranking in the top quartile of the pharmaceutical cohort for leverage.

Cash conversion metrics exceed the cohort median, indicating relatively efficient cash generation relative to operating income.

Capital expenditure as a percentage of revenue is above the cohort median, suggesting lower reinvestment requirements.

Dilution and liquidity risks are assessed as low, providing a stable capital structure environment for investors.

Revenue showed a year-over-year increase of 531.4% in the latest reported period compared to the prior year.

Net margin and operating margin are in the bottom quartile of the pharmaceutical cohort, signaling severe profitability issues.

Return on equity and return on assets are negative, underperforming the positive medians of the pharmaceutical peer group.

The company faces a high credit risk flag, indicating significant concerns regarding its ability to meet financial obligations.

Revenue declined by 4.7% annually over the four-year span from fiscal 2023 to the latest period.

Net income deteriorated significantly, reaching a loss of 4.78 billion JPY in the most recent fiscal year.

Revenue ¥233.5M, −11,6% YoY; Operating income −96,3% YoY.

• ▍Revenue ¥233.5M, −11,6% YoY
• ▍Operating income −96,3% YoY
• ▍Net income −81,7% YoY
• ▍Net margin -1028.6%

Revenue ¥336.8M, −39,3% YoY; Operating income −4,0% YoY.

• ▍Revenue ¥336.8M, −39,3% YoY
• ▍Operating income −4,0% YoY
• ▍Net income −22,5% YoY
• ▍Net margin -359.4%

Revenue ¥324.2M, −47,2% YoY; Operating income −8,7% YoY.

• ▍Revenue ¥324.2M, −47,2% YoY
• ▍Operating income −8,7% YoY
• ▍Net income +8,2% YoY
• ▍Net margin -369.1%

Revenue ¥382.6M, −44,3% YoY; Operating income −7,9% YoY.

• ▍Revenue ¥382.6M, −44,3% YoY
• ▍Operating income −7,9% YoY
• ▍Net income −37,1% YoY
• ▍Net margin -273.8%

Revenue ¥264.0M; Operating income -¥1.19B.

• ▍Revenue ¥264.0M
• ▍Operating income -¥1.19B
• ▍Net margin -500.5%

Revenue ¥554.5M; Operating income -¥1.14B.

• ▍Revenue ¥554.5M
• ▍Operating income -¥1.14B
• ▍Net margin -178.2%

Revenue ¥613.9M; Operating income -¥1.09B.

• ▍Revenue ¥613.9M
• ▍Operating income -¥1.09B
• ▍Net margin -212.3%

Revenue ¥686.6M; Operating income -¥908.3M.

• ▍Revenue ¥686.6M
• ▍Operating income -¥908.3M
• ▍Net margin -111.3%

Revenue ¥1.31B, −46,7% YoY; Operating income −13,7% YoY.

• ▍Revenue ¥1.31B, −46,7% YoY
• ▍Operating income −13,7% YoY
• ▍Net income −24,6% YoY
• ▍Net margin -365.3%

Revenue ¥2.45B, −56,1% YoY; Operating income −206,3% YoY.

• ▍Revenue ¥2.45B, −56,1% YoY
• ▍Operating income −206,3% YoY
• ▍Net income −95,3% YoY
• ▍Net margin -156.3%

Revenue ¥5.59B, −44,1% YoY; Operating income −163,0% YoY.

• ▍Revenue ¥5.59B, −44,1% YoY
• ▍Operating income −163,0% YoY
• ▍Net income −266,4% YoY
• ▍Free cash flow −270,7% YoY
• ▍Net margin -35.1%

Revenue ¥10.01B, +21,2% YoY; Operating income +103,7% YoY.

• ▍Revenue ¥10.01B, +21,2% YoY
• ▍Operating income +103,7% YoY
• ▍Net income −42,0% YoY
• ▍Free cash flow −40,4% YoY
• ▍Net margin 11.8%